Berkshire Asset Management LLC PA lowered its stake in shares of Allergan PLC. (NYSE:AGN) by 3.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,852 shares of the company’s stock after selling 64 shares during the period. Berkshire Asset Management LLC PA’s holdings in Allergan PLC. were worth $450,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GWM Advisors LLC raised its position in shares of Allergan PLC. by 0.4% in the first quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock valued at $300,000 after buying an additional 5 shares during the last quarter. Burns J W & Co. Inc. NY raised its position in shares of Allergan PLC. by 0.7% in the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock valued at $220,000 after buying an additional 6 shares during the last quarter. Trust Co raised its position in shares of Allergan PLC. by 0.8% in the first quarter. Trust Co now owns 1,224 shares of the company’s stock valued at $292,000 after buying an additional 10 shares during the last quarter. JNBA Financial Advisors raised its position in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the last quarter. Finally, Tarbox Group Inc. raised its position in shares of Allergan PLC. by 0.6% in the first quarter. Tarbox Group Inc. now owns 2,393 shares of the company’s stock valued at $572,000 after buying an additional 15 shares during the last quarter. 84.77% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Allergan PLC. (NYSE AGN) traded up 0.31% during mid-day trading on Friday, hitting $232.91. The company’s stock had a trading volume of 960,958 shares. The company has a 50-day moving average of $246.34 and a 200 day moving average of $238.00. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The company has a market cap of $78.07 billion, a price-to-earnings ratio of 7.10 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.25%. The business had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the business earned $3.35 earnings per share. The company’s revenue was up 8.8% on a year-over-year basis. On average, analysts expect that Allergan PLC. will post $16.27 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a dividend of $0.70 per share. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.21%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

TRADEMARK VIOLATION NOTICE: “Allergan PLC. (NYSE:AGN) Position Cut by Berkshire Asset Management LLC PA” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/allergan-plc-nyseagn-position-cut-by-berkshire-asset-management-llc-pa/1474297.html.

AGN has been the topic of several research reports. Cowen and Company set a $400.00 target price on Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, June 8th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Mizuho dropped their target price on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a research report on Friday, June 9th. Cantor Fitzgerald initiated coverage on Allergan PLC. in a research report on Friday, June 16th. They issued a “neutral” rating and a $231.00 target price on the stock. Finally, Zacks Investment Research raised Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research report on Tuesday, July 11th. Eight investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $274.49.

In related news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.